$HASI

Jefferies cuts HA Sustainable Infrastructure stock price target on capital efficiency view

Jefferies reduced its price target for HA Sustainable Infrastructure (HASI) to $44 from $45 but kept a Buy rating. The stock trades at $35.82, with analysts seeing ~40% upside. Jefferies cited improved capital efficiency and a 4.75% dividend yield. Other analysts have mixed views, with Mizuho raising its target to $50 and UBS downgrading to Neutral. HASI's performance is driven by spread discipline and origination volume.

Original reporting
Published Oct 1, 2026, 1:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 1:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$HASI
Bearish
medium confidence
Mentioned
$HASI
Relevance
4/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$HASIBearishLow
01

Why it matters

Analyst target cuts could temper short-term price momentum, but the Buy rating and dividend yield may support the stock.

02

Market read

The news is primarily relevant to traders focused on HASI and similar infrastructure finance stocks.

03

What to watch

Potential upside from the CCH2 initiative and dividend yield may be underappreciated.

Relevance 4/10Novelty 2/10Timing: today

Background

The article summarizes recent analyst actions on HA Sustainable Infrastructure Capital, including price target changes and dividend information.

Company-level read

Ticker impact

$HASIBearishMedium confidence
Context

Jefferies lowered its price target for HA Sustainable Infrastructure Capital to $44 from $45, maintaining a Buy rating.

Expected impact

likely pressure as the market prices in the lower target

Evidence & confidence

Analyst cut indicates reduced upside expectations, which may temper buying interest.

Market effects

Analyst revisions may influence other infrastructure finance stocks.

Limited to US-listed infrastructure finance sector.

Low, as the company is a niche player.

Counterpoint

Some investors may view the unchanged Buy rating as a buying opportunity despite the lower target.

Key entities

  • HA Sustainable Infrastructure Capital

    US-listed infrastructure finance firm (NYSE:HASI).

  • Jefferies

    Equity research firm providing the price target revision.

Related articles

$PRGMed

Q2 Rundown: PROG (NYSE:PRG) Vs Other Specialty Finance Stocks

Encore Capital Group (PRG) reported Q2 revenue of $491.9M, up 11.3% YoY, beating estimates. HASI reported $36.32M, down 64.9% YoY, missing estimates. TSLX reported $97.84M, down 14.9% YoY, beating estimates. MAIN reported $149.6M, up 3.9% YoY, topping estimates. PRG stock is up 10.4%, HASI up 8.1%, TSLX up 3.1%, and MAIN up 2.5% since reporting.

$HASIMedAI 8/10

Why Is HA Sustainable Infrastructure Capital (HASI) Stock Soaring Today

HA Sustainable Infrastructure Capital (HASI) shares rose about 7.5% after Q2 results beat expectations and management raised longer-term guidance. Adjusted EPS was $0.75, above forecasts, on revenue of about $120.8 million (+17% YoY). Managed assets grew ~20% to $17.6B. 2028 adjusted EPS guidance increased to $3.55-$3.65 from $3.50-$3.60; shares closed at $40.66 (+6.7%).

$HASIMed

HASI Announces Second Quarter 2026 Results and Raises Guidance on 24% Y/Y Adjusted EPS Growth YTD and Adjusted ROE Above 15%

HA Sustainable Infrastructure Capital, Inc. (HASI) filed an SEC Form 8-K — Results of Operations and Financial Condition. HASI Announces Second Quarter 2026 Results and Raises Guidance on 24% Y/Y Adjusted EPS Growth YTD and Adjusted ROE Above 15% ANNAPOLIS, Md., August 6, 2026 -- (BUSINESS WIRE) -- HA Sustainable Infrastructure Capital, Inc. (“HASI,” “we,” “our” or the “Company”) (NYSE: HASI), a lea

$REGNMed

Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)

Regeneron Pharmaceuticals reported initial trial results for ubamatamab, showing a 73% objective response rate and 11-month median progression-free survival in 11 patients with advanced low-grade serous ovarian cancer (LGSOC). The company plans to advance the drug into a Phase 3 trial and discuss the data with the FDA. LGSOC is a rare form of ovarian cancer with limited treatment options.